Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of apixaban in acute coronary syndrome
2005-004338-42Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apixaban in acute coronary syndrome (ACS) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Primary safety endpoint: bleeding events and Efficacy analyses. Started May 2006; status: completed.
02
Drugs
apixaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2005-004338-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004338-42.